Clinical Trial Data Governance: Roles, Controls and Audit

Clinical trial data governance is the set of roles, rules and controls that decide who owns trial data, who may see or change it, and how every action on it is recorded. Done well, it keeps a trial inspection-ready from first patient in to archive, protects participant privacy, and lets sponsors reuse trial data for new research without breaking the consent participants gave.
Why clinical trial data governance matters now
Trials now draw data from far more places than a single electronic data capture (EDC) system. Wearables, electronic health records, central labs, imaging vendors, genomic sequencing partners and patient-reported outcome apps all feed the same study. Each source arrives with its own format, its own owner and its own privacy terms. Without governance, that mix becomes a set of copies scattered across vendors, with no single answer to the questions an inspector or an ethics committee will ask.
Regulation has moved in the same direction. The International Council for Harmonisation updated its Good Clinical Practice guideline as ICH E6(R3), which puts weight on risk-based quality management, data integrity across the whole data life cycle and proportionate oversight of computerized systems. In the US, 21 CFR Part 11 still governs electronic records and signatures. In Europe, the General Data Protection Regulation (GDPR) and the coming European Health Data Space (EHDS) shape how trial data can be reused for secondary research. Governance is how a sponsor shows it meets all of these at once.
The secondary use question is the one most teams underestimate. Trial data is some of the cleanest, best-annotated health data that exists, and sponsors want to pool it across studies to find new signals. The May 2026 UK Biobank incident showed what happens when approved users can move data out through a normal workflow: no rule was broken, but the architecture allowed it. Trial data deserves stronger protection than that.
The core roles in clinical trial data governance
Clear roles come before any tool. Most governance failures trace back to a decision nobody owned.
Data owner and sponsor
The sponsor is accountable for the trial data and for the decisions about its use. In practice a named data owner, often in clinical data management or biostatistics, signs off on access, reuse and retention. That person needs authority to say no.
Data steward
Stewards look after the data day to day: data standards, coding dictionaries, query resolution and the mapping of source data to submission formats such as CDISC SDTM. They are the people who know what a field actually means.
Data access committee
For secondary use, a data access committee reviews each request against the consent, the protocol and the sponsor’s policy. It approves a defined purpose, a defined dataset and a defined period, not open-ended access.
Privacy and security leads
The data protection officer and the security team set the rules for de-identification, encryption, retention and incident response. They also decide which outputs are safe to release.
The controls that make governance real
Policies only matter if systems enforce them. These are the controls inspectors and auditors look for.
Access control by role and purpose
Every user gets the minimum access their role needs, for the purpose that was approved. A statistician analyzing efficacy does not need direct identifiers. A medical monitor reviewing safety may need more. Access should expire when the purpose ends.
Audit trails
Every create, change and delete is recorded with who, what, when and why. ICH E6(R3) and 21 CFR Part 11 both expect audit trails that cannot be switched off or edited by ordinary users. For secondary research, the audit trail should also record every query run and every result exported.
Data integrity under ALCOA+
Regulators judge trial records against the ALCOA+ principles: attributable, legible, contemporaneous, original and accurate, plus complete, consistent, enduring and available. Governance turns those words into checks: source data verification, locked database states and controlled changes after lock.
Consent tracking
Each participant’s consent, including any later withdrawal or narrowing, has to travel with their data. Reuse for a new question is only allowed where the consent supports it.
Output checking
When researchers analyze pooled trial data, the results they export are checked before release so that no individual can be identified. An automated airlock makes that check consistent and fast instead of a manual bottleneck.
Centralized versus federated governance for trial data
Most sponsors start by copying trial data into one central repository. That works for a single study. It becomes harder when data sits with several partners, in several countries, under different laws. A federated model keeps each dataset where it is and sends approved analysis to it, so data never leaves the source.
| Dimension | Central repository | Federated model |
|---|---|---|
| Where trial data lives | Copied into one store | Stays with each sponsor, site or partner |
| Cross-border transfer | Needed for every pooled study | Not needed; analysis travels instead |
| Access enforcement | One set of permissions over all copies | Each custodian keeps its own rules |
| Audit trail | Covers the central copy only | Every query and output logged at each source |
| Consent changes | Must be pushed to every copy | Applied once, at the source |
| Risk of bulk data leaving | Possible through normal export | Blocked by design; only checked results leave |
A Trusted Research Environment is the usual way to put the federated model into practice. It gives approved researchers a secure workspace with analysis tools, while the custodian keeps control of the data and of what comes out.
How governance works across a trial’s life cycle
Study start-up
Write the data management plan and the governance plan together. Name the owner, stewards and access committee. Decide which data standards apply, how consent will be captured and which future uses the consent form allows.
Conduct
Apply role-based access in every system, from EDC to imaging. Monitor risk indicators as ICH E6(R3) expects, and keep the audit trail complete. Treat each new data source, such as a wearable vendor, as a governance decision, not just an integration task.
Database lock and submission
Lock the database under a documented procedure. Control any change after lock. Keep the mapping from source to submission datasets traceable so a reviewer can follow any number back to its origin.
Secondary use and archive
After the primary analysis, trial data often becomes most valuable when combined with other studies or with real-world data. Route every request through the access committee, check it against consent, run analysis inside a controlled environment and release only checked outputs. Harmonizing trial data to a common model makes pooling far easier; our guide to data harmonization explains the approach.
Common gaps in clinical trial data governance
The same weak spots appear again and again when sponsors review their setup.
- Vendor copies nobody tracks. Each vendor keeps its own extract, and nobody can say how many copies of the trial data exist or who can open them.
- Consent that stops at the site. Withdrawals are recorded in the site file but never reach the analysis datasets that reuse the data later.
- Audit trails that end at entry. Systems log edits to case report forms but not the queries and exports that happen during analysis.
- Manual output review. One person checks result tables by eye, so checks vary and requests queue for weeks.
- Access that never expires. Accounts created for one study stay open long after it ends.
Each of these is a governance decision that was never made. Fixing them is usually cheaper than explaining them to an inspector.
Practical next steps
- Map every source of trial data and name an owner for each.
- Write down which secondary uses your consent forms allow, study by study.
- Check that audit trails cover analysis and export, not just data entry.
- Replace manual output review with consistent, automated checks.
- Decide where pooling needs data to move, and where analysis can move instead.
- Test the setup with a mock inspection before you need a real one.
Clinical trial data governance is not a document that sits on a shelf. It is the set of decisions and controls that let a sponsor prove, at any moment, that its trial data is accurate, protected and used only as participants agreed.
Frequently asked questions
What is clinical trial data governance?
It is the framework of roles, policies and system controls that decides who owns trial data, who can access or change it, and how every action is recorded, from study start-up through secondary use and archive.
How does ICH E6(R3) affect data governance?
ICH E6(R3) emphasizes risk-based quality management and data integrity across the whole data life cycle, including oversight of computerized systems. Sponsors need governance that shows how data is protected and traced at every step.
What is the difference between a data owner and a data steward?
The data owner is accountable for decisions about the data, such as access and reuse. The data steward manages the data day to day, including standards, coding and quality.
Can trial data be reused for new research?
Yes, where participant consent and local law allow it. Each request should go through a data access committee, run in a controlled environment and release only checked results.
Why use a federated model for trial data?
A federated model keeps each dataset with its custodian and sends approved analysis to it. That avoids cross-border copies, keeps consent changes in one place and stops bulk data from leaving.
What do auditors look for in trial data governance?
Complete audit trails, role-based access, controlled changes after database lock, evidence of ALCOA+ data integrity and clear records of who approved each use of the data.
